Insulin-like growth factor-I prevents lethal acute liver failure induced by D-galactosamine and lipopolysaccharide in rats

In Vivo. 2003 May-Jun;17(3):293-9.

Abstract

The aim of this study was to evaluate the effect of insulin-like growth factor-I (IGF-I) on lethality and liver function in experimental acute liver failure. Intravenous co-administration of D-galactosamine (GalN) and lipopolysaccharide (LPS) to rats induced high mortality and marked increases in aspartate aminotransferase, alanine aminotransferase and total bilirubin, associated with hypoglycemia. One-hour pre-treatment with IGF-I significantly prevented lethality and blood parameter changes in rats. Histological examination also showed that massive hepatocellular hemorrhagic necrosis and inflammatory cell infiltration around peri-central veins in the liver, as well as shrinkage of cytoplasm and nuclear condensation, were induced by GalN plus LPS injection, but these all were improved by pre-treatment with IGF-I. Overall, this study showed that IGF-I treatment resulted in effective prevention of lethal acute liver failure in rats induced by GalN plus LPS, suggesting a therapeutic potential for IGF-I in the prevention of acute liver failure.

MeSH terms

  • Alanine Transaminase / blood
  • Animals
  • Aspartate Aminotransferases / blood
  • Bilirubin / blood
  • Disease Models, Animal
  • Galactosamine / administration & dosage
  • Galactosamine / toxicity*
  • Humans
  • Injections, Intravenous
  • Insulin-Like Growth Factor I / therapeutic use*
  • Lipopolysaccharides / administration & dosage
  • Lipopolysaccharides / toxicity*
  • Liver / drug effects
  • Liver / pathology*
  • Liver Failure, Acute / chemically induced*
  • Liver Failure, Acute / pathology*
  • Liver Failure, Acute / prevention & control*
  • Rats
  • Recombinant Proteins / therapeutic use

Substances

  • Lipopolysaccharides
  • Recombinant Proteins
  • Insulin-Like Growth Factor I
  • Galactosamine
  • Aspartate Aminotransferases
  • Alanine Transaminase
  • Bilirubin